Mainstay Products in Urology Fiscal 2013 sales: ¥28.2 billion Fiscal 2013 sales: ¥133.8 billion Mainstay Products in Immunology (including Transplantation) and Infectious Diseases Fiscal 2013 sales: ¥181.1 billion Fiscal 2013 sales: ¥36.1 billion In highly specialized therapeutic areas including urology and transplantation, Astellas has created innovative new  drugs such as overactive bladder (OAB) treatments and an immunosuppressant, and has established a global  competitive advantage. Vesicare is a treatment for OAB that helps to relieve  associated symptoms such as urinary urgency, frequent  urination and urinary incontinence. Launched in Europe  in 2004, it is now sold in approximately 80 countries  and regions. This is an OAB treatment with a different mechanism of  action from Vesicare. After its initial launch in Japan in 2011  with the brand name of Betanis, the product has been  successively launched in the U.S. and in Europe with the  brand name of Myrbetriq and BETMIGA, respectively. It is  currently sold in over 25 countries and regions. This product is an immunosuppressant used to sup- press organ rejection in organ transplants. It is sold in  approximately 100 countries and regions and has made  a significant global contribution to the field of  transplantation. This product is a candin-type antifungal agent that treats  fungal infections with a mechanism of action that inhibits  cell wall biosynthesis. It is sold in approximately 50  countries and regions. Astellas Pharma Inc.  _ Annual Report 2014 20 Candin-type antifungal agent Funguard/MycAMinE Immunosuppressant prograf, Advagraf/Graceptor/ ASTAGRAF Xl Treatment for OAB vesicare Treatment for OAB Betanis/Myrbetriq/BETMiGA (Generic name: mirabegron) prOduCT pOrTfOliO TO SuppOrT GrOwTh (*Sales are shown based on ifrS)